drugset / Trial / NCT04017962
A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection
Phase 2
Completed
102 enrolled
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine of letermovir (LTC) is effective at preventing Cytomegalovirus (CMV) infection from returning in people who have already had CMV infection after a bone marrow transplant.
Timeline
- Start
- 2019-07-19
- Primary completion
- 2024-08-07
- Completion
- 2025-07-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Letermovir | Small molecule | 240 mg | Oral |
| Subject | Letermovir | Small molecule | 480 mg | Oral |